AUS
NZ
UK
CA
USA
IND
Highlights:
Symbion to distribute Spontan, an innovative nasal spray for erectile dysfunction, across its extensive pharmacy network.
Collaboration supports LTR Pharma’s early access program and establishes a scalable distribution framework.
Spontan’s intranasal delivery system demonstrates significantly faster absorption compared to oral alternatives.
LTR Pharma (ASX:LTP) has entered a strategic agreement with Symbion Pty Ltd to distribute Spontan, a novel nasal spray treatment for erectile dysfunction. As one of Australia's leading pharmaceutical wholesalers, Symbion operates a vast network that services thousands of pharmacies across the country. This collaboration ensures broad accessibility for Spontan, reinforcing LTR Pharma’s commitment to making this innovative treatment widely available.
Agreement and Distribution Network
The partnership is structured as a non-exclusive agreement, encompassing critical distribution elements such as warehousing, inventory control, and logistics management. Symbion will implement specialized handling protocols and quality assurance measures to support Spontan’s nationwide availability. Additionally, integration efforts will focus on streamlining pharmacy ordering systems and developing pharmacist education materials to ensure proper product awareness.
Market Expansion and Early Access Program
LTR Pharma’s collaboration with Symbion aligns with its broader strategy to establish a scalable supply chain ahead of Spontan’s full commercial rollout. The agreement also enhances access through the Therapeutic Goods Administration (TGA) Authorised Prescriber Scheme, allowing qualified prescribers to provide Spontan under early access provisions. This initiative ensures patients receive innovative treatment options while regulatory processes continue.
Distinctive Intranasal Delivery for Faster Absorption
Spontan leverages an advanced intranasal delivery system to administer a PDE5 inhibitor, setting it apart from traditional oral treatments. The nasal cavity’s vascular structure facilitates rapid and uniform absorption, leading to significantly faster onset compared to oral alternatives. Clinical trials have demonstrated that Spontan achieves a much quicker absorption time, which enhances convenience and effectiveness for users.
Ongoing Partnerships and Expanded Reach
Beyond the collaboration with Symbion, LTR Pharma is working with other organizations to extend Spontan’s market reach. The agreement with Mens Health Downunder strengthens supply chain efficiency, while a partnership with Restorative Sexual Health Clinic supports the growing telehealth sector. These initiatives aim to enhance accessibility and streamline patient engagement across various healthcare channels.
Commitment to Industry Standards and Accessibility
LTR Pharma’s executive chairman, Lee Rodne, underscores the importance of these partnerships in ensuring reliable distribution and adherence to high pharmaceutical standards. The collaboration with Symbion reflects a dedication to building a robust supply chain, ensuring compliance with regulatory frameworks, and enhancing overall market readiness. By working with established industry leaders, LTR Pharma continues to support the seamless availability of Spontan throughout Australia.
This article was developed in collaboration with LTR Pharma. Please seek independent financial advice before making any financial decisions.
